Gregory Wade

Oncothyreon (NASDAQ: ONTY) plunged Tuesday after the company's tecemotide lung cancer treatment failed to show any effects in a trial in Japan. Merck KGaA has exclusive rights to develop and commercialize the drug and informed Oncothyreon it would discontinue the Phase I/II study....

Shares of Novavax (NASDAQ: NVAX) reach 52-week high at $4.46, up 15.245% following Wedbush analyst Gregory Wade significantly raised the price target from $4 to $12. Wade noted higher revised expectations on the RSV/ flu combo product format. The analyst noted that Wedbush's model predicts that...

In a report published Tuesday, Wedbush analyst Gregory Wade initiated an Outperform rating on MacroGenics (NASDAQ: MGNX) and a price target of $70.00. In the report, Wedbush says "Novel immunoregulatory therapeutics (PD1, PDL1, CTLA4, IDO, B7-H3, CD-27, CD-47) are elevating the likelihood for...

In a report published on Friday, Wedbush analyst Gregory Wade upgraded Oncothyreon (NASDAQ: ONTY) from Neutral to Outperform and raised the price target from $2.00 to $5.00. In the report, Wedbush noted, "Merck KGaA(Merck Serono) reported new analysis of the Phase III data from the completed L-...